CLRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cellectar Biosciences Inc (CLRB) is not a strong buy at this time for a beginner investor with a long-term strategy. The stock lacks clear positive catalysts, has weak financial performance, and no strong trading signals or analyst support. While insider buying is a positive indicator, the company's poor financials and lack of trend momentum make it unsuitable for immediate investment.
The MACD is positive and expanding, indicating a slight bullish momentum. RSI is neutral at 65.967, and moving averages are converging, suggesting indecision in the market. The stock is trading near its first resistance level (R1: 3.565), with key support at 3.121. Overall, the technical indicators do not provide a strong buy signal.
Insider buying has increased significantly by 1385.12% over the last month, indicating potential confidence from insiders.
No recent news or events to drive positive sentiment. Financial performance is weak, with a significant drop in net income (-69.70% YoY) and EPS (-87.39% YoY). The company has no revenue growth and no clear valuation metrics. Additionally, there are no recent trading signals or congress trading data to support a buy decision.
In Q3 2025, the company showed no revenue growth (0% YoY), a net income drop of -69.70% YoY to -$4,443,877, and an EPS decline of -87.39% YoY to -1.41. Gross margin remains at 0%. Overall, the financials are weak and do not support a buy recommendation.
No data available for analyst ratings or price target changes.
